Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scots HTA approves four products, but more disappointment for Roche's Perjeta

This article was originally published in Scrip

Executive Summary

Scotland's health technology assessment agency, the Scottish Medicines Consortium (SMC), has given the go-ahead for four products to be used on NHS Scotland, including a first HTA nod for Lundbeck's alcohol dependency drug Selincro (nalmefene). Unfortunately for Roche, however, the SMC was not moved to recommend breast cancer drug Perjeta (pertuzumab), a further blow after NICE too rejected the product. Roche has accused the Scottish system of being "not fit for purpose."

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023047

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel